Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SEER
SellSinkerSeer, Inc. · Healthcare · United States · $110M · Avg Vol: $761K/d
28
StockRankGet insider-trade alerts
Q
31
V
37
M
49
P/E (TTM)
—
ROE
-26.4%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.7M | 15.2M | 13.9M | 16.1M | 3.2% | 14.2M | 15.7M | 18.9M | 8.2% |
| EPS | -1.49 | -1.35 | -1.39 | -1.28 | — | -1.22 | -1.10 | -1.02 | — |
| Shares | 63.4M | 64.3M | 59.1M | 56.2M | -11.3% | 55.4M | — | — | — |
| Debt | 29.9M | 28.3M | 26.0M | 23.7M | -7.5% | 22.4M | — | — | — |
| Equity | 447.0M | 396.9M | 327.6M | 259.3M | -16.6% | — | — | — | — |
| Op CF | -60.8M | -59.1M | -46.1M | -44.4M | — | -43.4M | — | — | — |
| Inv CF | -122.7M | 37.9M | 65.9M | 61.5M | — | — | — | — | — |
| Fin CF | 3.9M | 0.5M | -11.5M | -10.6M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-6.7%
SMA 50SMA 200
Close
$1.94
RSI (14)
28.0
52W High
$2.41
From 52W High
0.8%
SCORE BREAKDOWN
Quality
31
ROIC
-26.6%26.2
ROE
-26.4%27.0
GP/Assets
2.3%14.9
Op. Margin
-542.9%9.8
FCF/Assets
-16.8%23.2
Piotroski
431.0
Int. Cover
—N/A
D/E Ratio
0.10x62.3
Current Ratio
14.74x92.6
Value
37
P/E (TTM)
—N/A
EV/EBITDA
0.3x25.0
P/FCF
—N/A
P/B
0.5x97.3
P/S
7.6x31.2
Div Yield
—N/A
Momentum
49
52W High %
80%67.8
RS 6M
-4%61.1
SMA 50/200
1.09x73.7
EPS Rev 4W
-4.1%15.0
EPS Rev 12W
—N/A
EPS Improve
+16%32.0
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$110M
P/E (Forward)
-1.9x
Gross Margin
47.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SEER are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SEER | Seer, Inc.(you) | $110M | 28 | Sell |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 27 | Sell |
| PTHS | Pelthos Therapeutics Inc. | $95M | 25 | Sell |
| OKUR | OnKure Therapeutics, Inc. | $153M | 27 | Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 23 | Sell |
| EQ | Equillium, Inc. | $152M | 29 | Sell |
| ATRA | Atara Biotherapeutics, Inc. | $92M | 23 | Sell |
| APLM | Apollomics, Inc. | $77M | 29 | Sell |
| XBIT | XBiotech Inc. | $69M | 27 | Sell |
| ACET | Adicet Bio, Inc. | $85M | 22 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%